The EU came up short in running any pan-European clinical trials to advance the development of COVID-19 vaccines and therapies. It is now trying to fix the problem and be better prepared for future health emergencies
Experts believe that new uses of real-world data could help address Europe’s health challenges, if trust is built into the system. A high-level event in Berlin, convened by Science|Business and EIT Health, explored the potential ways forward
The pandemic accelerated open science and cemented social media as a place for scientists to discuss their research. But 32% of researchers in a new survey said they or a colleague faced online abuse after posting their findings
Science led the way out of the COVID-19 pandemic and can rise to other challenges, as long as there is sustained investment in research and research infrastructures, the head of the European Molecular Biology Lab tells Science|Business
Development of vaccines and therapeutics is highly risky and takes time. New models are needed to ensure we are prepared for fresh outbreaks of disease and emerging infections
The EU succeeded in creating a portfolio of vaccines and procuring enough doses to go round, but contracts did not make provisions for disruptions to supplies
Clinical trials were halted as COVID-19 took hold. But inability to see patients face-to-face has inspired the use of technology to monitor patients remotely, leading to improvements that are here to stay
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.